Dashboard
Manage Tickers

ABBV


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch
Cannabis Meets Prescription Drugs, Steroid...
05/18/2024 14:19:14

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...

abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion--analyst
AbbVie Is 'Successfully Positioned To Abso...
05/17/2024 17:47:16

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...

the-analyst-verdict-abbvie-in-the-eyes-of-5-experts
The Analyst Verdict: AbbVie In The Eyes Of...
05/17/2024 13:00:43

abbvie-says-it-will-present-new-data-supporting-leading-gastroenterology-portfolio-at-2024-digestive-disease-week-company-to-present-15-abstracts-including-three-oral-presentations-in-crohns-disease-and-ulcerative-colitis
AbbVie Says It Will Present New Data Suppo...
05/17/2024 11:34:26

The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.  Data to be...

cantor-fitzgerald-initiates-coverage-on-abbvie-with-overweight-rating-announces-price-target-of-200
Cantor Fitzgerald Initiates Coverage On Ab...
05/17/2024 11:16:23

Cantor Fitzgerald analyst Louise Chen initiates coverage on AbbVie (NYSE:ABBV) with a Overweight rating and announces Price ...

1000-invested-in-this-stock-5-years-ago-would-be-worth-2000-today
$1000 Invested In This Stock 5 Years Ago W...
05/16/2024 16:30:24

unpacking-the-latest-options-trading-trends-in-abbvie
Unpacking the Latest Options Trading Trend...
05/14/2024 17:31:06

abbvie-enters-into-collaboration-and-option-to-license-agreement-with-gilgamesh-pharmaceuticals-for-therapies-for-psychiatric-disorders
AbbVie Enters Into Collaboration And Optio...
05/13/2024 12:40:40

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop nex...

abbv---analyzing-abbvies-short-interest
(ABBV) - Analyzing AbbVie's Short Interest
05/10/2024 19:15:20

health-canada-approves-abbvies-qulipta-for-chronic-migraine-prevention-in-adults
Health Canada Approves AbbVie's QULIPTA Fo...
05/08/2024 12:05:24

1000-invested-in-this-stock-10-years-ago-would-be-worth-3100-today
$1000 Invested In This Stock 10 Years Ago ...
05/02/2024 18:30:17

Core News & Articles
CNBC Halftime Report Final Trades: Amazon....
04/30/2024 17:01:00

barclays-maintains-overweight-on-abbvie-lowers-price-target-to-187
Barclays Maintains Overweight on AbbVie, L...
04/29/2024 15:26:59

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $195 to $187.

peeling-back-the-layers-exploring-abbvie-through-analyst-insights
Peeling Back The Layers: Exploring AbbVie ...
04/29/2024 15:01:09

bmo-capital-maintains-outperform-on-abbvie-lowers-price-target-to-180
BMO Capital Maintains Outperform on AbbVie...
04/29/2024 14:09:17

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $19...

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

arthritis-patients---cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost
Arthritis Patients - Cigna's Evernorth To ...
04/26/2024 18:41:57

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...

tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-whats-driving-markets-friday
Tech Stocks Rebound As Magnificent 7 Roar ...
04/26/2024 17:45:42

Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in...

ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-profit-outlook
Ex-Humira Growth Platform Drives AbbVie's ...
04/26/2024 13:54:00

AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immun...

abbvie-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-financial-results-and-raised-its-fy24-adjusted-eps-guidance-above-estimates
AbbVie shares are trading higher after the...
04/26/2024 11:43:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION